Dana-Farber Cancer Institute
Dr. Paul G. Richardson, MD received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, UK and then was chief resident at the Royal Marsden Hospital, London, UK. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, Boston, Massachusetts he joined Dana-Farber Cancer Institute (DFCI), Boston, MA in 1994. He completed his medical residency at Beth Israel Hospital, and joined DFCI's Jerome Lipper Multiple Myeloma Center in 1999, becoming its clinical director in 2001.
OPTIMISMM: investigating an alternative therapy for lenalidomide-refractory patients
Do results obtained in clinical trials translate accurately in real world practice?
Defibrotide: still early days but a promising outlook for veno-occlusive disease
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Defibrotide to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome in AML & ALL